The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Mario Santinami
No Relationships to Disclose
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Roche/Genentech (Inst)
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Marta Nyakas
Consulting or Advisory Role - Incyte (Inst); MSD Oncology (Inst); Novartis (Inst)
 
Caroline Dutriaux
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Andrew Mark Haydon
Honoraria - Merck; Novartis
Consulting or Advisory Role - Novartis; Pierre Fabre
Speakers' Bureau - Merck; Novartis
 
Laurent Mortier
No Relationships to Disclose
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pierre Fabre; Roche
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christine-Elke Ortmann
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Egbert De Jong
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Richard Kefford
Consulting or Advisory Role - Amgen (Inst); TEVA (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)